Cardiovascular Systems, Inc., a US-based medical technology firm, has gained recognition as a leading company for developing and selling products to treat coronary artery disease and peripheral artery diseases worldwide. The enterprise provides several plaque treatments, such as calcified plaque, for all types of plaque occurring in the knee and above regions. It additionally offers peripheral support therapy to address the barriers posed by catheter, surgical, and pharmacological alternatives. The company's coronary artery disease product, Diamondback 360 Coronary orbital atherectomy systems (OAS), is intended to enhance the delivery of stent products for CAD patients who qualify for percutaneous transluminal coronary angioplasty or stenting. Besides, the firm supplies guidewires, catheters, balloons, embolic protection systems, and other OAS support products to users. Cardiovascular Systems, Inc. has initiated a partnership with Chansu Vascular Technologies, LLC, with a focus on making novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. has its headquarters in Saint Paul, Minnesota, and originated in 1989 as Shturman Cardiology Systems, Inc. before it rebranded to its current name in January 2003.
Cardiovascular Systems's ticker is CSII
The company's shares trade on the NASDAQ stock exchange
They are based in St. Paul, Minnesota
There are 501-1000 employees working at Cardiovascular Systems
It is csi360.com
Cardiovascular Systems is in the Healthcare sector
Cardiovascular Systems is in the Medical Appliances & Equipment industry
The following five companies are Cardiovascular Systems's industry peers: